Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dociparstat sodium - Cantex Pharmaceuticals

Drug Profile

Dociparstat sodium - Cantex Pharmaceuticals

Alternative Names: CX-01; DSTAT; ODSH; PGX-100; PGX-ODSH-2013-AML-1

Latest Information Update: 19 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ParinGenix
  • Developer Cantex Pharmaceuticals; Chimerix
  • Class Anti-inflammatories; Anticoagulants; Antineoplastics; Heparins; Ischaemic heart disorder therapies; Polysaccharides
  • Mechanism of Action Cathepsin G inhibitors; Chemokine CXCL12 inhibitors; CXCR4 receptor antagonists; HMGB1 protein inhibitors; Leucocyte elastase inhibitors; P selectin inhibitors; Platelet factor 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Acute lung injury; Acute myeloid leukaemia; Blood coagulation disorders; Brain injuries; Chronic obstructive pulmonary disease; Lung cancer; Myelodysplastic syndromes; Myocardial infarction; Pancreatic cancer; Reperfusion injury; Solid tumours; Thrombocytopenia

Most Recent Events

  • 12 Jul 2022 Chimerix terminates the license and development agreement with Cantex for dociparstat sodium
  • 31 Dec 2021 Chimerix has several US and foreign issued patents and pending US and foreign applications for Dociparstat sodium in USA prior to December 2021
  • 20 May 2021 Chimerix terminates a phase II/III trial for Acute lung injury (associated with COVID-19 infections) in USA (IV) (NCT04389840)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top